CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study.

Joan Calvet Jordi GratacosMaría José AmengualMaria LlopMarta NavarroAmàlia MorenoAntoni Berenguer LlergoAlejandra SerranoCristóbal OrellanaManel Cervantes

Published in: Viruses (2020)

A predictive value and treatment considerations for lymphocyte subsets are suggested, especially for CD3CD4+ T cells. Lymphocyte subsets determination at hospital admission is recommended.

Keyphrases

peripheral blood
sars cov
healthcare
high resolution
acute care
combination therapy
replacement therapy